A single-arm, phase II trial of locally advanced head and neck squamous cell carcinoma patients.
Latest Information Update: 11 Jan 2025
Price :
$35 *
At a glance
- Drugs Toripalimab (Primary)
- Indications Head and neck cancer; Oropharyngeal cancer
- Focus Therapeutic Use
- 11 Jan 2025 New trial record